Ian Anthony James Lorimer
Affiliations: | Biochemistry, Microbiology and Immunology | University of Ottawa, Ottawa, ON, Canada |
Area:
Biochemistry, Cell Biology, OncologyWebsite:
http://www.ohri.ca/profile/ilorimerGoogle:
"Ian Anthony James Lorimer"Bio:
Parents
Sign in to add mentor| Bishnu D. Sanwal | grad student | 1989 | Western University (Chemistry Tree) | |
| (Regulation of cAMP-dependent protein kinases during skeletal myogenesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lorimer IA. (2019) Aberrant Rac pathway signalling in glioblastoma. Small Gtpases. 1-15 |
| Jacques FH, Nicholas G, Lorimer I, et al. (2019) Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study. Journal of Clinical Oncology. 37 |
| Lorimer I, Lavictoire S, Jomaa D, et al. (2019) Csig-12. Prex1 Links Aberrant Pi 3-Kinase Pathway Signaling To Maintenance Of The Neural Stem Cell-Like Phenotype Of Glioblastoma Cells Neuro-Oncology. 21 |
| Kumar R, Lorimer I. (2018) Csig-06. The Molecular Subtype Of Primary Glioblastoma Cells Correlates With Response To Therapeutic Agents That Induce Apoptosis Or Senescence Neuro-Oncology. 20 |
| Gont A, Daneshmand M, Woulfe J, et al. (2016) PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion. Oncotarget |
| Restall IJ, Parolin DA, Daneshmand M, et al. (2015) PKCι DEPLETION INITIATES MITOTIC SLIPPAGE-INDUCED SENESCENCE IN GLIOBLASTOMA. Cell Cycle (Georgetown, Tex.). 0 |
| Jahani-Asl A, Yin H, Soleimani V, et al. (2015) CSIG-06EGFRvIII REQUIRES OSMR AS A CO-RECEPTOR TO DRIVE GLIOBLASTOMA PATHOGENESIS Neuro-Oncology. 17: v67.2-v67 |
| Gont A, Hanson JE, Lavictoire SJ, et al. (2014) Inhibition of glioblastoma malignancy by Lgl1. Oncotarget. 5: 11541-51 |
| Karapetis CS, Jonker D, Daneshmand M, et al. (2014) PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 744-53 |
| Goss GD, O'Callaghan C, Lorimer I, et al. (2013) Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3320-6 |